AG Pro Biosimilars. [Biosimilars unter der Lupe]. https://probiosimilars.de/publikationen/marktdaten/ (2023).
Kay, J. et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann. Rheum. Dis. 77, 165–174 (2018).
Google Scholar
European Medicines Agency. Biosimilars in the EU. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf (2019).
Cohen, H. P. & McCabe, D. The importance of countering biosimilar disparagement and misinformation. BioDrugs 34, 407–414 (2020).
Google Scholar
Alten, R. et al. Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. Int. J. Rheum. Dis. 23, 1514–1525 (2020).
Google Scholar
Cohen, S. B. et al. Long-term efficacy, safety, and immunogenicity of the infliximab (IFX) biosimilar, PF-06438179/GP1111, in patients with rheumatoid arthritis after switching from reference IFX or continuing biosimilar therapy: week 54-78 data from a randomized, double-blind, phase III trial. BioDrugs 34, 197–207 (2020).
Google Scholar
Toupin-April, K. et al. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. Semin. Arthritis Rheum. 51, 593–600 (2021).
Google Scholar
Kravvariti, E., Kitas, G. D., Mitsikostas, D. D. & Sfikakis, P. P. Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat. Rev. Rheumatol. 14, 727–740 (2018).
Google Scholar
Dutt, K., Srinivasan, A. & Van Langenberg, D. The nocebo effect in a non-medical switching program from originator to biosimilar infliximab in inflammatory bowel disease. BioDrugs 36, 639–644 (2022).
Google Scholar
Glintborg, B. et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann. Rheum. Dis. 76, 1426–1431 (2017).
Google Scholar
